Eli Lilly Revenue Jumps on Sales of Weight-Loss Drug
The drug maker raised its full-year revenue and earnings guidance, driven by Mounjaro and Zepbound sales. Shares rose 7% premarket.
The drug maker raised its full-year revenue and earnings guidance, driven by Mounjaro and Zepbound sales. Shares rose 7% premarket.
